Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials

Find Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials Near You

PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Maximum Age: 75
Healthy Volunteers: f
View:

• Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below

• Life expectancy ≥ 12 months.

• Ability to communicate in English

• Presence of a stable caregiver

Locations
United States
Arizona
Barrow Neurological Institute
RECRUITING
Phoenix
Florida
University of Miami
RECRUITING
Miami
Contact Information
Primary
Neuralink Clinical Team
clinical-team-ct@neuralink.com
(877) 398-4465
Time Frame
Start Date: 2024-01-09
Estimated Completion Date: 2031-01
Participants
Target number of participants: 15
Treatments
Experimental: Neuralink N1 Implant and R1 Robot
Implantation of the N1 Implant by the R1 Robot.
Sponsors
Leads: Neuralink Corp

This content was sourced from clinicaltrials.gov